Nektar Therapeutics (NKTR)

Last Year

26-Apr-23 -- 25-Apr-24

Time Period:

0 Net Amount

Buy:	0	--
Sell:	0	--

Company Sentiment

Drug Delivery

Drugs

Sentiment Breakdown by Insider

0

(3)

0

(2)

6

(1)

24

0

0

+1

0

+2

0

+3

Two Year Chart

26-Apr-22 -- 25-Apr-24

Price ($)

Two Year Stock Price Chart

Sentiment

Buy & Sell Volume ($)

Two Year Insider Trading Volume Chart

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
15-Jun-23 6:26 PM View:	14-Jun-23 Sale ($17.10K)	Whitfield Roy A Director		Nektar Therapeutics - NKTR	(9%) 317.75K to 287.75K	0	0	--	--	Show Txns Hide Txns

22-Feb-24 8:16 PM View:	20-Feb-24 Sale ($13.62K)	Robin Howard W President & CEO Director		Nektar Therapeutics - NKTR	(8%) 960.57K to 880.3K	0	0	--	--	Show Txns Hide Txns

20-Sep-23 8:06 PM View:	18-Sep-23 Sale ($3.01K)	Ajer Jeffrey Robert Director		Nektar Therapeutics - NKTR	(11%) 38.51K to 34.15K	0	0	--	--	Show Txns Hide Txns

22-Feb-24 8:19 PM View:	20-Feb-24 Sale ($6.13K)	Zalevsky Jonathan Chief R&D Officer		Nektar Therapeutics - NKTR	(13%) 303.18K to 265.02K	0	0	--	--	Show Txns Hide Txns

20-Sep-23 8:09 PM View:	18-Sep-23 Sale ($3.01K)	Myriam Curet Director		Nektar Therapeutics - NKTR	(14%) 31.78K to 27.42K	0	0	--	--	Show Txns Hide Txns

22-Feb-24 8:17 PM View:	20-Feb-24 Sale ($5.17K)	Wilson Mark Andrew Chief Legal Officer		Nektar Therapeutics - NKTR	(11%) 265.22K to 236.67K	0	0	--	--	Show Txns Hide Txns